Late-onset NPM1 mutation in a MYC-amplified relapsed/refractory acute myeloid leukemia patient treated with gemtuzumab ozogamicin and glasdegib

Affiliations

• ¹ Department of Internal Medicine V, Heidelberg University Hospital.
• ² Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Barcelona.
• ³ Department of Internal Medicine V, Heidelberg University Hospital, Germany; Molecular Medicine Partnership Unit (MMPU), University of Heidelberg and European Molecular Biology Laboratory, Heidelberg.
• ⁴ Department of Internal Medicine V, Heidelberg University Hospital, Germany; NCT-Trial Center, National Center of Tumor Diseases, Heidelberg University Hospital and German Cancer Research Center.
• ⁵ Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Barcelona, Spain; Universitat Pompeu Fabra (UPF), Barcelona.
• ⁶ Department of Internal Medicine V, Heidelberg University Hospital, Germany; Molecular Medicine Partnership Unit (MMPU), University of Heidelberg and European Molecular Biology Laboratory, Heidelberg. Caroline.Pabst@med.uni-heidelberg.de.